the trials titrated on a fixed schedule, most people here dont, worth remembering when comparing
#semaglutide 2025-09-06
- manila_meniscus — the appetite effect faded for me around 3 months and going up fixed it for a while 14:54
- shame_and_meds — £120 a month for compounded against what brand costs locally is why most people here use vials 18:03
- shame_and_meds — sorry to jump in mine faded too 18:46
- shame_and_meds — genuine question STEP 1 ran to 68 weeks. thats the one everyone half remembers 19:56
- VialBot — Assay note: Homopeptide lot H-2814 reported at 96.8% of label content. 21:24
seven days ish
the appetite effect faded for me around 3 months and going up fixed it for a while
vial units and pen clicks are different systems, mixing the two is how people end up wrong
not the same trial
went to 2.4 and the extra suppression wasnt worth the GI for me, so i came back down, anyway
does the licensed ceiling for weight differ from the diabetes one
vials not pens here
is the plateau at 34 weeks normal or am i doing something wrong
whats the actual licensed ceiling, i keep seeing different numbers
if youre comparing brand to compounded, dose accuracy in the vial is the variable, not the molecule
went 1 to 1.7 too fast and spent two weeks regretting it, dropped back and repeated the step
held at 0.25 and lost 39lb over 9 months, slower than the trials and fine by me
restarted after 8 months off at a low dose and the nausea arrived exactly like the first time, i could be wrong
moving my dose day by a day or two never did anything noticeable for me
i held at 0.25 for 9 months and it was the best decision i made
slower worked better
for the archive does the seven day half life mean the last two days are weaker
my Medutest report on the QYB vial came back 99.2 against a certificate saying 98.6
i dont think the plateau is a dose problem most of the time, but i cant prove that
steady state takes weeks
STEP is several trials, so saying STEP said x is usually wrong without a number after it
2.4 is the ceiling
my 20 vial in 5ml gives 10mg/ml so 7.5 lands on 30 units, thats why i picked that volume
| Trial schedule | What most people here do | |
|---|---|---|
| Step interval | 4 weeks, fixed | 4-12 weeks, on symptoms |
| Holding | protocol deviation | normal and expected |
| Top dose | reached by design | often never reached |
| Coming down | not studied | common at maintenance |
thats STEP 1
SELECT was cardiovascular outcomes in people with overweight and existing disease, not a weight trial
[edited]lost about 25kg on the low doses before i even got to 1, which surprised me
*Medutest not the other one
licensed ceiling for weight is 2.4 weekly, anything above that is not a licensed dose
same dose day
anyone compared their 8 vial dosing against the pen increments
[edited]im 4 months in at 0.25 and the appetite effect faded, is that a thing
£120 a month for compounded against what brand costs locally is why most people here use vials
| Trial schedule | What most people here do | |
|---|---|---|
| Step interval | 4 weeks, fixed | 4-12 weeks, on symptoms |
| Holding | protocol deviation | normal and expected |
| Top dose | reached by design | often never reached |
| Coming down | not studied | common at maintenance |
held there too
does anyone actually run a five week step instead of four
right so 20 months at 2.4 and the honest summary is diminishing returns after the first half
my dose day drifted from friday to sunday, does that reset anything
was STEP 4 the one that ran to 68 weeks or am i mixing them up
sorry to jump in mine faded too
*sorry, FGP
give it four weeks
i was wrong about the ceiling for a year, i thought 3 existed. it doesnt for the weight indication
genuine question STEP 1 ran to 68 weeks. thats the one everyone half remembers
half life is about a week so youre roughly four to five weeks to steady state on any new dose
how many weeks before you noticed anything at 2.4
*week 31 not week 6
how long did the first 9kg take for people at the low doses
SELECT wasnt weight
Batch lookup A-2418: 4 independent reports on file, earliest 2024-11-14.
Assay note: Homopeptide lot H-2814 reported at 96.8% of label content.